NCT04142762View on ClinicalTrials.gov

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

January 12, 2020

Study Completion Date

January 29, 2020

Conditions
Chronic Hepatitis B
Interventions
DRUG

ABI-H2158

ABI-H2158 tablets

DRUG

Itraconazole

Itraconazole capsules

DRUG

Rifampin

Rifampin capsules

DRUG

Midazolam

Midazolam syrup

DRUG

Ethinyl Estradiol / Levonorgestrel

Ethinyl Estradiol / Levonorgestrel tablets

DRUG

Esomeprazole

Esomeprazole capsules

DRUG

Placebo matching oral contraceptive

Placebo matching Ethinyl Estradiol / Levonorgestrel tablets

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Assembly Biosciences

INDUSTRY

NCT04142762 - A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults | Biotech Hunter | Biotech Hunter